1. Home
  2. GBX vs LTGO Comparison

GBX vs LTGO Comparison

Compare GBX & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenbrier Companies Inc. (The)

GBX

Greenbrier Companies Inc. (The)

HOLD

Current Price

$43.04

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$20.82

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GBX
LTGO
Founded
1974
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
1996
2026

Fundamental Metrics

Financial Performance
Metric
GBX
LTGO
Price
$43.04
$20.82
Analyst Decision
Sell
Analyst Count
2
0
Target Price
$49.00
N/A
AVG Volume (30 Days)
316.8K
218.2K
Earning Date
04-07-2026
N/A
Dividend Yield
2.85%
N/A
EPS Growth
28.02
N/A
EPS
2.21
N/A
Revenue
$3,240,200,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.74
N/A
P/E Ratio
$18.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.23
$17.22
52 Week High
$59.19
$25.93

Technical Indicators

Market Signals
Indicator
GBX
LTGO
Relative Strength Index (RSI) 47.47 44.55
Support Level $41.27 N/A
Resistance Level $48.66 $20.49
Average True Range (ATR) 0.90 1.86
MACD 0.15 -0.36
Stochastic Oscillator 82.73 7.31

Price Performance

Historical Comparison
GBX
LTGO

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: